Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Origin Bio
AddedJul 3, 2026
UpdatedJul 6, 2026
Origin Bio

Origin Bio

Generates spatial, molecular, and functional maps of patient tumors to power cancer therapeutic discovery.

HQ
San Francisco, CA, US
Founded
2025
Accelerator
Y Combinator logoY CombinatorW26
Overview
Analysis
Compare
Employees
News

Origin Bio studies cancer biology directly in patient tissue, generating spatial, molecular, and functional maps from tumor samples so that gene activity and cellular behavior can be observed in their native context. The company is assembling large patient-derived single-cell datasets intended to support drug discovery and to be licensed to pharmaceutical and AI partners.

Its research combines wet-lab tissue analysis with computational models for predicting regulatory activity and programming gene expression. The team draws on backgrounds in computing and bioengineering and works with academic scientific advisors, positioning its data and models as a foundation for developing cancer therapeutics.

Origin Bio - Products & Services

  • Origin Bio — Cancer Biology Platform logo

    Origin Bio — Cancer Biology Platform

    A tissue-first platform generating spatial, molecular, and functional maps from patient tumors.

Origin Bio - Similar Companies

AtlasXomics logo

AtlasXomics

atlasxomics.com

Genesis Therapeutics logo

Genesis Therapeutics

Exonic logo

Exonic

exonic.ai

Mana.bio logo

Mana.bio

mana.bio

Origin logo

Origin

originww.com

Tempus logo

Tempus

tempus.com

Mission Bio logo

Mission Bio

TRex Bio logo

TRex Bio

trex.bio

Generate Biomedicines logo

Generate Biomedicines

Exai Bio logo

Exai Bio

exai.bio

BioMap logo

BioMap

biomap.com

PredxBio logo

PredxBio

predxbio.com

Gordion Bioscience logo

Gordion Bioscience

gordion.bio

64x Bio logo

64x Bio

64xbio.com

GEn1E Lifesciences logo

GEn1E Lifesciences

gen1e.com

Origin Bio - Quick Facts

Who are Origin Bio's competitors?

Companies similar to Origin Bio include AtlasXomics, Genesis Therapeutics, Exonic and Mana.bio.

When was Origin Bio founded?

Origin Bio was founded in 2025.

Where is Origin Bio's headquarters located?

Origin Bio's headquarters is located in San Francisco, CA, US.

How many employees does Origin Bio have?

Origin Bio has 5 employees as of Jul 4, 2026.

Origin Bio - Classification

Industry
  • AI
  • Biotechnology
Ownership
  • Private
Technology
  • Genomics
  • Machine Learning
Model
  • AI Platform
Revenue
  • B2B
  • Licensing
Customer
  • B2B
  • Pharmaceutical Manufacturers